<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157248</url>
  </required_header>
  <id_info>
    <org_study_id>1160.42</org_study_id>
    <nct_id>NCT00157248</nct_id>
  </id_info>
  <brief_title>Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048</brief_title>
  <official_title>Long-term, Open-label Follow-up Treatment of Patients With Atrial Fibrillation Who Have Been Previously Treated With BIBR 1048 in the PETRO Trial (Trial 1160.20 - NCT01227629). (PETRO Extension Trial: PETRO-Ex)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To determine the long term safety and efficacy of BIBR 1048 in patients with chronic atrial
      fibrilla tion, with or without concomitant chronic treatment with acetylsalicylic acid (ASA).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2003</start_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yearly Event Rate for Composite Endpoint of Stroke, Transient Ischaemic Attacks, System Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and Mortality.</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first occurrence of stroke, transient ischaemic attacks, system thromboembolism, myocardial infarction, other major adverse cardiac events and mortality. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Yearly Event Rate for Major Bleeding</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first occurrence of fatal or life-threatening, retroperitoneal, intracranial, intraocular, or intraspinal bleeding, which required surgical treatment, led to a transfusion of a minimum of 2 units of packed cells or whole blood, or led to a fall in hemoglobin of 20g/L or less.
Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Yearly Event Rate for Major + Minor/Relevant Bleeding</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first occurrence of either major or minor/relevant bleeding. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Yearly Event Rate for Any Bleeding</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first occurrence of any bleeding event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Yearly Event Rate for Minor Bleeding</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first occurrence of minor bleeding. A minor bleeding event is any bleed that does not qualify as a major bleed. All minor bleeding events not fulfilling one of the criteria for clinically relevant were classified as nuisance bleeds.
Clinically-relevant was defined as spontaneous skin hematoma ≥25 cm², spontaneous nose bleed &gt;5 min, macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention, spontaneous rectal bleeding, gingival bleeding &gt;5 min, leading to hospitalization, leading to a transfusion of &lt;2 units of packed cells or whole blood and any other bleeding event considered clinically relevant by the investigator.
Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yearly Event Rate for Stroke</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first occurrence of any fatal or non-fatal stroke. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yearly Event Rate of Ischaemic Stroke</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first occurrence of any ischaemic stroke. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yearly Event Rate of Haemorrhagic Stroke</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first occurrence of any haemorrhagic stroke. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yearly Event Rate for Transient Ischaemic Attacks</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first occurrence of any transient ischaemic attacks. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yearly Event Rate for Systemic Thromboembolism</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first occurrence of any non-central nervous system systemic thromboembolism.
Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yearly Event Rate of Myocardial Infarction</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first occurrence of any myocardial infarction. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yearly Event Rate of Other Major Adverse Cardiac Events</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first occurrence of any other major adverse cardiac events. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yearly Event Rate of Death</measure>
    <time_frame>5 years</time_frame>
    <description>Time to death of any cause. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yearly Event Rate for Composite Secondary Endpoint of Ischaemic Stroke, Transient Ischaemic Attacks, Non-central Nervous System Systemic Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and All-cause Mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first occurrence of ischaemic stroke, transient ischaemic attacks, non-central nervous system systemic thromboembolism, myocardial infarction, other major adverse cardiac events and all-cause mortality.
Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Adverse Event</measure>
    <time_frame>5 years</time_frame>
    <description>Frequency of patients with severe adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Analyses</measure>
    <time_frame>5 years</time_frame>
    <description>Frequency of patients with possible clinically significant abnormalities, i.e. with values out of normal range.
Normal ranges are defined as:
Alanine aminotransferase (ALT): 5-45 [U/L]
Aspartate aminotransferase (AST): 10-40 [U/L]
Bilirubin, total: 0.2-1.0 [mg/dL]</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">361</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>dabigatran etexilate, 150 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage used at study start</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran etexilate, 150 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage used at study start</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran etexilate, 300 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage used at study start</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran etexilate, 300 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage used at study start</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>dosage used at study start</description>
    <arm_group_label>dabigatran etexilate, 150 mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>dosage used at study start</description>
    <arm_group_label>dabigatran etexilate, 150 mg twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>dosage used at study start</description>
    <arm_group_label>dabigatran etexilate, 300 mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>dosage used at study start</description>
    <arm_group_label>dabigatran etexilate, 300 mg twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria Diagnosis and main criteria for inclusion: Paroxysmal, persistent, or
        permanent (chronic) non-rheumatic atrial fibrillation with a history of coronary artery
        disease (CAD)

        Inclusion Criteria:

          -  previous treatment with BIBR 1048 in PETRO (trial 1160.20- NCT01227629) and no
             premature discontinuation of therapy

          -  paroxysmal, persistent, or permanent (chronic) non-rheumatic atrial fibrillation,
             documented by electrocardiogram (ECG) at least twice prior to enrollment in PETRO

          -  concomitant coronary artery disease -an additional risk factor for stroke (one or more
             of the following conditions/events): hypertension, diabetes mellitus (DM), congestive
             heart failure (CHF) or Left ventricular dysfunction (LVD), previous ischemic stroke or
             transient ischemic attack) TIA, or age greater than 75 years. -age &gt;= 18 years

          -  written, informed consent

        Exclusion criteria

        Exclusion Criteria:

          -  Valvular heart disease conferring significantly increased risk of thromboembolic
             events (e.g. clinically significant mitral stenosis or prosthetic valves). planned
             cardioversion while patients are in the study.

          -  contraindication to anticoagulant therapy (previous intracranial hemorrhage,
             gastro-intestinal (GI) hemorrhage within previous 3 months, previous severe hemorrhage
             with warfarin at therapeutic international normalized ratio (INR), regular use of
             non-steroidal anti-inflammatory drugs, hemorrhagic diathesis) major bleeding within
             the last 6 months (other than GI hemorrhage).

          -  severe renal impairment (estimated glomerular filtration rate [GFR] &lt;= 30 mL/min).
             uncontrolled hypertension (systolic blood pressure [SBP] &gt; 180 mm Hg and/or diastolic
             blood pressure [DBP] &gt; 100 mmHg).

          -  Women who are pregnant or of childbearing potential who refuse to use a medically
             acceptable form of contraception throughout the study (note: a negative pregnancy test
             must be obtained for any woman of childbearing potential prior to entry into the
             study).

          -  Patients who have received an investigational drug other than BIBR 1048 within the
             last 30 days.

          -  Patients considered unreliable by the investigator concerning the requirements for
             follow-up during the study and/or compliance with study drug administration. Another
             indication for anticoagulant treatment (eg, deep vein thrombosis or pulmonary
             embolus). Clinically significant anemia (note: patients with mild-moderate anemia
             should only be enrolled after the possibility of a GI bleeding source has been
             evaluated, the etiology of the anemia identified, and appropriate action taken).
             Patients suffering from thrombocytopenia (platelets &lt; 100,000/uL). Any other condition
             which, in the discretion of the investigator, would not allow safe participation in
             the study.

          -  Continuing or planned concomitant treatment with antiplatelet agents other than
             acetylsalicylic acid (ASA).

          -  Recent malignancy or radiation therapy (&lt;= 6 months).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.42.10003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.10006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.10004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.10002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.10015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.10008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westminster</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.10012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.10007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.10014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.10013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.10009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.10001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.45010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.45005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.45007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brædstrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.45011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.45012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frederikssund</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsingør</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.45009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Holbæk</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.45014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Køge</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.45013 Roskilde Sygehus</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.45006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Svendborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.31003 Ziekenhuis Amstelveen</name>
      <address>
        <city>Amstelveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.31001 Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.31013 Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.31008 Gelre Ziekenhuis, locatie Juliana</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.31006 Wilhelmina Ziekenhuis</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.31007 Gemini Ziekenhuis</name>
      <address>
        <city>Den Helder</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.31002 Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.31014 Ziekenhuisgroep Twente</name>
      <address>
        <city>Hengelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.31012 Vasculair onderzoekscentrum (VOC)</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.31009 Havenziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.31004 Maasland Ziekenhuis</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.31005 Tweesteden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.31011 Maxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.46013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eskilstuna</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.46007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jönköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.46010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.46009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.46008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norrköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.46011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.46006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Umeaa</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.42.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>November 18, 2010</results_first_submitted>
  <results_first_submitted_qc>January 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2011</results_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a non-randomized open-label extension study of study 1160.20. Patients initially continued Dabigatran treatment of 1160.20; per protocol amendment, most patients moved to 150 mg bid. All events were assigned to the Dabigatran regimen that a patient received prior to the event and patients may be counted in multiple regimens</recruitment_details>
      <pre_assignment_details>In this non-randomized follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran Etexilate, 150 mg QD (Once Daily)</title>
          <description>Dosage used at study start</description>
        </group>
        <group group_id="P2">
          <title>Dabigatran Etexilate, 150 mg BID (Twice Daily)</title>
          <description>Dosage used at study start</description>
        </group>
        <group group_id="P3">
          <title>Dabigatran Etexilate, 300 mg QD (Once Daily)</title>
          <description>Dosage used at study start</description>
        </group>
        <group group_id="P4">
          <title>Dabigatran Etexilate, 300 mg BID (Twice Daily)</title>
          <description>Dosage used at study start</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98">Started: Participant completed previous trial on Dabigatran and took study drug of present trial.</participants>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50">Completed: Participant without premature discontinuation of study medication.</participants>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>site closures, subject moving</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients in follow-up study.</population>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran Etexilate, 150 mg QD (Once Daily)</title>
          <description>Dosage used at study start</description>
        </group>
        <group group_id="B2">
          <title>Dabigatran Etexilate, 150 mg BID (Twice Daily)</title>
          <description>Dosage used at study start</description>
        </group>
        <group group_id="B3">
          <title>Dabigatran Etexilate, 300 mg QD (Once Daily)</title>
          <description>Dosage used at study start</description>
        </group>
        <group group_id="B4">
          <title>Dabigatran Etexilate, 300 mg BID (Twice Daily)</title>
          <description>Dosage used at study start</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="124"/>
            <count group_id="B5" value="361"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.4" spread="8.6"/>
                    <measurement group_id="B2" value="69.3" spread="8.2"/>
                    <measurement group_id="B3" value="71.0" spread="6.8"/>
                    <measurement group_id="B4" value="68.8" spread="8.5"/>
                    <measurement group_id="B5" value="69.7" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="112"/>
                    <measurement group_id="B5" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atrial fibrillation</title>
          <description>Atrial fibrillation measured at baseline</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Persistent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="139"/>
                    <measurement group_id="B2" value="38" spread="40"/>
                    <measurement group_id="B3" value="15" spread="38"/>
                    <measurement group_id="B4" value="46" spread="15"/>
                    <measurement group_id="B5" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Permanent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paroxysmal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Yearly Event Rate for Composite Endpoint of Stroke, Transient Ischaemic Attacks, System Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and Mortality.</title>
        <description>Time to first occurrence of stroke, transient ischaemic attacks, system thromboembolism, myocardial infarction, other major adverse cardiac events and mortality. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate for Composite Endpoint of Stroke, Transient Ischaemic Attacks, System Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and Mortality.</title>
          <description>Time to first occurrence of stroke, transient ischaemic attacks, system thromboembolism, myocardial infarction, other major adverse cardiac events and mortality. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="17.0"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="5.7"/>
                    <measurement group_id="O5" value="4.5"/>
                    <measurement group_id="O6" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Yearly Event Rate for Stroke</title>
        <description>Time to first occurrence of any fatal or non-fatal stroke. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate for Stroke</title>
          <description>Time to first occurrence of any fatal or non-fatal stroke. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="1.1"/>
                    <measurement group_id="O5" value="1.7"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Yearly Event Rate of Ischaemic Stroke</title>
        <description>Time to first occurrence of any ischaemic stroke. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate of Ischaemic Stroke</title>
          <description>Time to first occurrence of any ischaemic stroke. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="1.7"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Yearly Event Rate of Haemorrhagic Stroke</title>
        <description>Time to first occurrence of any haemorrhagic stroke. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate of Haemorrhagic Stroke</title>
          <description>Time to first occurrence of any haemorrhagic stroke. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.6"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Yearly Event Rate for Transient Ischaemic Attacks</title>
        <description>Time to first occurrence of any transient ischaemic attacks. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate for Transient Ischaemic Attacks</title>
          <description>Time to first occurrence of any transient ischaemic attacks. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.2"/>
                    <measurement group_id="O5" value="0.4"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Yearly Event Rate for Systemic Thromboembolism</title>
        <description>Time to first occurrence of any non-central nervous system systemic thromboembolism.
Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate for Systemic Thromboembolism</title>
          <description>Time to first occurrence of any non-central nervous system systemic thromboembolism.
Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="8.5"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.2"/>
                    <measurement group_id="O5" value="0.4"/>
                    <measurement group_id="O6" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Yearly Event Rate of Myocardial Infarction</title>
        <description>Time to first occurrence of any myocardial infarction. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate of Myocardial Infarction</title>
          <description>Time to first occurrence of any myocardial infarction. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.1"/>
                    <measurement group_id="O5" value="0.4"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Yearly Event Rate of Other Major Adverse Cardiac Events</title>
        <description>Time to first occurrence of any other major adverse cardiac events. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate of Other Major Adverse Cardiac Events</title>
          <description>Time to first occurrence of any other major adverse cardiac events. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="8.5"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.1"/>
                    <measurement group_id="O5" value="0.8"/>
                    <measurement group_id="O6" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Yearly Event Rate of Death</title>
        <description>Time to death of any cause. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate of Death</title>
          <description>Time to death of any cause. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="2.7"/>
                    <measurement group_id="O5" value="2.1"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Yearly Event Rate for Major Bleeding</title>
        <description>Time to first occurrence of fatal or life-threatening, retroperitoneal, intracranial, intraocular, or intraspinal bleeding, which required surgical treatment, led to a transfusion of a minimum of 2 units of packed cells or whole blood, or led to a fall in hemoglobin of 20g/L or less.
Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate for Major Bleeding</title>
          <description>Time to first occurrence of fatal or life-threatening, retroperitoneal, intracranial, intraocular, or intraspinal bleeding, which required surgical treatment, led to a transfusion of a minimum of 2 units of packed cells or whole blood, or led to a fall in hemoglobin of 20g/L or less.
Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="6.6"/>
                    <measurement group_id="O4" value="3.1"/>
                    <measurement group_id="O5" value="0.8"/>
                    <measurement group_id="O6" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Yearly Event Rate for Major + Minor/Relevant Bleeding</title>
        <description>Time to first occurrence of either major or minor/relevant bleeding. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate for Major + Minor/Relevant Bleeding</title>
          <description>Time to first occurrence of either major or minor/relevant bleeding. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="8.5"/>
                    <measurement group_id="O3" value="11.6"/>
                    <measurement group_id="O4" value="7.6"/>
                    <measurement group_id="O5" value="6.6"/>
                    <measurement group_id="O6" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Yearly Event Rate for Any Bleeding</title>
        <description>Time to first occurrence of any bleeding event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate for Any Bleeding</title>
          <description>Time to first occurrence of any bleeding event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="25.5"/>
                    <measurement group_id="O3" value="21.5"/>
                    <measurement group_id="O4" value="14.7"/>
                    <measurement group_id="O5" value="14.9"/>
                    <measurement group_id="O6" value="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Yearly Event Rate for Composite Secondary Endpoint of Ischaemic Stroke, Transient Ischaemic Attacks, Non-central Nervous System Systemic Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and All-cause Mortality</title>
        <description>Time to first occurrence of ischaemic stroke, transient ischaemic attacks, non-central nervous system systemic thromboembolism, myocardial infarction, other major adverse cardiac events and all-cause mortality.
Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate for Composite Secondary Endpoint of Ischaemic Stroke, Transient Ischaemic Attacks, Non-central Nervous System Systemic Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and All-cause Mortality</title>
          <description>Time to first occurrence of ischaemic stroke, transient ischaemic attacks, non-central nervous system systemic thromboembolism, myocardial infarction, other major adverse cardiac events and all-cause mortality.
Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="17.0"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="5.5"/>
                    <measurement group_id="O5" value="4.5"/>
                    <measurement group_id="O6" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Adverse Event</title>
        <description>Frequency of patients with severe adverse events.</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Adverse Event</title>
          <description>Frequency of patients with severe adverse events.</description>
          <population>All treated patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Yearly Event Rate for Minor Bleeding</title>
        <description>Time to first occurrence of minor bleeding. A minor bleeding event is any bleed that does not qualify as a major bleed. All minor bleeding events not fulfilling one of the criteria for clinically relevant were classified as nuisance bleeds.
Clinically-relevant was defined as spontaneous skin hematoma ≥25 cm², spontaneous nose bleed &gt;5 min, macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention, spontaneous rectal bleeding, gingival bleeding &gt;5 min, leading to hospitalization, leading to a transfusion of &lt;2 units of packed cells or whole blood and any other bleeding event considered clinically relevant by the investigator.
Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly Event Rate for Minor Bleeding</title>
          <description>Time to first occurrence of minor bleeding. A minor bleeding event is any bleed that does not qualify as a major bleed. All minor bleeding events not fulfilling one of the criteria for clinically relevant were classified as nuisance bleeds.
Clinically-relevant was defined as spontaneous skin hematoma ≥25 cm², spontaneous nose bleed &gt;5 min, macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention, spontaneous rectal bleeding, gingival bleeding &gt;5 min, leading to hospitalization, leading to a transfusion of &lt;2 units of packed cells or whole blood and any other bleeding event considered clinically relevant by the investigator.
Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25</description>
          <population>All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.</population>
          <units>yearly event rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinically relevant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="8.5"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="4.5"/>
                    <measurement group_id="O5" value="5.8"/>
                    <measurement group_id="O6" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nuisance only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="17.0"/>
                    <measurement group_id="O3" value="9.9"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="8.3"/>
                    <measurement group_id="O6" value="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Analyses</title>
        <description>Frequency of patients with possible clinically significant abnormalities, i.e. with values out of normal range.
Normal ranges are defined as:
Alanine aminotransferase (ALT): 5-45 [U/L]
Aspartate aminotransferase (AST): 10-40 [U/L]
Bilirubin, total: 0.2-1.0 [mg/dL]</description>
        <time_frame>5 years</time_frame>
        <population>All treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Once Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O2">
            <title>50 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O3">
            <title>150 mg Once Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O4">
            <title>150 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
          </group>
          <group group_id="O5">
            <title>300 mg Once Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
          </group>
          <group group_id="O6">
            <title>300 mg Twice Daily</title>
            <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Analyses</title>
          <description>Frequency of patients with possible clinically significant abnormalities, i.e. with values out of normal range.
Normal ranges are defined as:
Alanine aminotransferase (ALT): 5-45 [U/L]
Aspartate aminotransferase (AST): 10-40 [U/L]
Bilirubin, total: 0.2-1.0 [mg/dL]</description>
          <population>All treated patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST &gt; 3*ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt; 3*ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin &gt; 2*ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.</desc>
      <group_list>
        <group group_id="E1">
          <title>50 mg Once Daily</title>
          <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily</description>
        </group>
        <group group_id="E2">
          <title>50 mg Twice Daily</title>
          <description>Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily</description>
        </group>
        <group group_id="E3">
          <title>150 mg Once Daily</title>
          <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily</description>
        </group>
        <group group_id="E4">
          <title>150 mg Twice Daily</title>
          <description>Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily</description>
        </group>
        <group group_id="E5">
          <title>300 mg Once Daily</title>
          <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily</description>
        </group>
        <group group_id="E6">
          <title>300 mg Twice Daily</title>
          <description>Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="153" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Atrial conduction time prolongation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic inspiratory decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Myasthenic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Albuminuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Urethral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Joint prosthesis user</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="219" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="65" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="57" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

